Colorado-based biotechnology company leveraging AI to develop new medicines from naturally available materials, Enveda Biosciences, has raised $130 million in Series C funding round spearheaded by FVP and Kinnevik.
New and existing investors, including Premji Invest, Baillie Gifford, Lingotto Innovation, Dimension Capital, Lux Capital, True Ventures, The Nature Conservancy, Henry R. Kravis, and Cresset Partners, supported the investment round, which boosted the company’s total funding to $360 million.
Enveda will use the latest funding to unveil clinical catalysts in 2025 and 2026 across its programs with promising economic opportunities to further advance its pipeline of candidates and discovery programs.
The latest funding follows the company’s recent announcement of a clinical trial for its foundation model, which was trained on a vast collection of experiments.
Enveda Biosciences Drug Analysis Platform
Enveda Biosciences’ technology platform leverages AI and the abundance of biochemicals in nature to dramatically reduce the time taken to develop test, commercialize, and market new drugs.
By simplifying the drug development and commercialization processes, the company allows biopharmaceuticals to develop better medicine in the shortest time, especially during public health emergencies.
Enveda’s platform combines metabolomics, robotics, and machine learning to analyze natural samples for their chemical composition, structure, and therapeutic value, eliminating the need to isolate compounds and conduct extensive testing to ascertain their effectiveness.
This enables drug researchers to identify and characterize molecules and develop antibiotics much faster than using traditional drug discovery, development, and marketing methods.
